16.02.2016 • News

Oil Slump Makes Shell Scramble to Pay for BG

As it finally completed the £36 billion ($53 billion) mega merger with BG Group on Feb. 15, multinational oil and petrochemicals group Shell was still struggling with the logistics of shedding $30 billion of assets in the next three years at prices expected before the oil market plunged.

The takeover of British rival BG has transformed the Anglo-Dutch group into the world’s top player in liquefied natural gas (LNG) but it will have to scramble to sell assets and shed several thousand jobs to finance the deal, buy back shares and support dividends payments.

Shell has said it will “backload” the sale of its assets towards the end of the three-year period when oil prices may have recovered somewhat, while adding that it will focus its disposals initially on “oil price insensitive” business areas such as refining, lubricants and chemicals.

With the BG buy announced in spring 2015, the group is banking on rapid growth in the global LNG market. With the added critical mass, it has already passed Chevron to become the world's second-largest public oil and gas company by market value behind ExxonMobil.

Under the combined group’s business structure, BG – headed by Huibert Vigeveno – will become a wholly-owned subsidiary of Shell. The Dutch native headed the integration planning team and will oversee its implementation.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.